Join to view full profile
9500 Euclid AveCA-60Cleveland, OH 44195
Phone+1 216-445-7920
Fax+1 216-444-9464
Dr. Menefee is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Meharry Medical CollegeClass of 1999
Certifications & Licensure
OH State Medical License 2023 - 2027
MD State Medical License 2004 - 2025
DC State Medical License 2021 - 2024
FL State Medical License 2000 - 2022
GA State Medical License 2014 - 2017
MN State Medical License 2006 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification FirstNet (Clinical), Cerner Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2014-2015, 2017
Clinical Trials
- Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer Start of enrollment: 2009 Nov 03
- Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Publications & Presentations
PubMed
- 1 citationsPhase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.Joleen M. Hubbard, Jun Yin, Erin L. Schenk, Rui Qin, Joel M. Reid
Investigational New Drugs. 2021-09-13 - 22 citationsAn International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid CancerKeith C. Bible, Michael E. Menefee, Chia Chi Josh Lin, Michael Millward, William J. Maples
Thyroid. 2020-09-08 - 13 citationsFoundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.Nicole M. Iñiguez-Ariza, Sina Jasim, Mabel Ryder, Ashish V. Chintakuntlawar, John C. Morris
The Journal of Clinical Endocrinology and Metabolism. 2020-07-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
